Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 1.25% is 98% below its 5-year average of 50.44%, near the high end of its 5-year range (-1056.93%–66.39%).
100.54% above its 12-month average of -230.54%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -87.41%.
GROSS MARGIN
1.25%
GROSS MARGIN AVG TTM
-230.54%
GROSS MARGIN AVG 3Y
42.18%
GROSS MARGIN AVG 5Y
50.44%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+100.54%
CURRENT VS 3Y AVG
-97.04%
CURRENT VS 5Y AVG
-97.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.32%
median of 679 covered companies
CURRENT VS SECTOR MEDIAN
-96.82%
vs the sector median at left
Market Cap
$2.58M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.58M
Gross Margin
23.21%
TTM Avg
29.65%
3Y Avg
45.21%
5Y Avg
30.14%
Market Cap
$2.56M
Gross Margin
67.21%
TTM Avg
75.24%
3Y Avg
78.18%
5Y Avg
70.66%
Market Cap
$2.47M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.32M
Gross Margin
63.43%
TTM Avg
61.72%
3Y Avg
62.82%
5Y Avg
60.98%
Market Cap
$2.33M
Gross Margin
80.40%
TTM Avg
59.71%
3Y Avg
-452.13%
5Y Avg
-301.42%
Market Cap
$2.27M
Gross Margin
-628.02%
TTM Avg
-265.21%
3Y Avg
-2905.33%
5Y Avg
-2576.02%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iSpecimen Inc. (ISPC) | $2.64M | 1.25% | -230.54% | 42.18% | 50.44% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.58M | 0.00% | 0.00% | 0.00% | 0.00% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.58M | 23.21% | 29.65% | 45.21% | 30.14% |
| Nuwellis, Inc. (NUWE)vs › | $2.61M | 69.69% | 64.31% | 60.13% | 58.62% |
| Jaguar Health, Inc. (JAGX)vs › | $2.56M | 67.21% | 75.24% | 78.18% | 70.66% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.47M | 0.00% | 0.00% | 0.00% | 0.00% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | 63.43% | 61.72% | 62.82% | 60.98% |
| Onconetix, Inc. (ONCO)vs › | $2.33M | 80.40% | 59.71% | -452.13% | -301.42% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.27M | -628.02% | -265.21% | -2905.33% | -2576.02% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.04M | 0.00% | -310.04% | -329.59% | -274.54% |
Gross Margin
1.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -87.41% |
| 2026-03-31 | 45.89% |
| 2025-12-31 | -1056.93% |
| 2025-09-30 | -91.94% |
| 2025-06-30 | 37.71% |
| 2025-03-31 | 37.85% |
| 2024-12-31 | 10.26% |
| 2024-09-30 | 41.62% |
| 2024-06-30 | 50.26% |
| 2024-03-31 | 56.33% |
| 2023-12-31 | 44.58% |
| 2023-09-30 | 49.87% |
| 2023-06-30 | 47.47% |
| 2023-03-31 | 61.12% |
| 2022-12-31 | 52.40% |
| 2022-09-30 | 54.26% |
| 2022-06-30 | 57.25% |
| 2022-03-31 | 53.71% |
| 2021-12-31 | 52.05% |
| 2021-09-30 | 66.39% |
| 2021-06-30 | 48.72% |
| 2021-03-31 | 45.22% |
| 2020-12-31 | 42.84% |
| 2020-09-30 | 59.83% |
| 2020-06-30 | 68.50% |
| 2020-03-31 | 61.78% |
| 2019-12-31 | 51.87% |
| 2019-09-30 | 29.74% |
